case_images: PMC10587582_01
case_images: PMC10587582_02
case_images: (A) The alpha fetoprotein (AFP) levels of the patient during the treatment of sintilimab combined with IBI310; (B) The total amylase and P-amylase levels of the patient during the treatment; (C) The lipase levels of the patient during the treatment; (D) The abdominal CT scan of the patient at admission which revealed no signs of enlargement or inflammation of the pancreas.
case_images: fimmu-14-1274449-g001.jpg
case_images: PMC10587582_02_fimmu-14-1274449-g001.jpg
case_images: f1
case_images: The dynamic changes in serum levels of AFP, amylase and lipase are shown in  Figures 1A-C . The abdominal CT scan revealed no signs of enlargement or inflammation in this patient's pancreas ( Figure 1D ), and the serum levels of creatinine and eGFR were within normal range.
case_images: (A) Plain and enhanced CT of main lesions of the patient in different periods. a-i: right posterior lobe of the liver; j-r: right anterior lobe of the liver; s-a' the right anterior chest wall; b'j': the pancreas with no signs of any inflammation and enlargement. (B) This is a flowchart of the treatment of the patient. At different times, the patient received combination immunotherapy (sintilimab plus IBI310). CR, complete response, PR, partial response, SD, stable disease, AEs, adverse events.
case_images: fimmu-14-1274449-g002.jpg
case_images: PMC10587582_02_fimmu-14-1274449-g002.jpg
case_images: f2
case_images: August 31st, 2021.The flowchart of the treatment and the changes of the imaging examination is in  Figure 2 . Although levels of amylase and pancreatic amylase increased at the first two cycles of immunotherapy, the abdominal CT scan did not reveal any signs of enlargement or inflammation in the pancreas ( Figure 2 ).
case_images: PMC10587582_03
case_images: PMC10587582_04